The role of timed sequential chemotherapy in adult acute myelogenous leukemia.
Consecutive trials of timed sequential chemotherapy (TSC) have been conducted in adults with acute myelogenous leukemia. The rationale for TSC was based on the observation that leukemic cells can be recruited synchronously into the cell cycle after initial intensive therapy, at which time they may become more susceptible to killing by chemotherapeutic agents. Achieving complete remission is essential for prolonged disease-free survival and may affect long-term outcome. TSC has led to higher rates of complete remission and has improved long-term outcomes. This article reviews the results of important trials in which TSC was used as an induction regimen in de novo, relapsed, or refractory acute myelogenous leukemia or as postremission therapy.
Thomas
Xavier
X
Service d'Hématologie, Hôpital Edouard Herriot, Lyon Cedex 03, France. xavier.thomas@chu-lyon.fr
D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002453:Cell Cycle / Q000187:drug effects; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*
D000970:Antineoplastic Agents